24.64 USD
-0.20
0.81%
At close Oct 9, 4:00 PM EDT
1 day
-0.81%
5 days
-0.96%
1 month
23.45%
3 months
48.26%
6 months
53.81%
Year to date
-5.45%
1 year
4.36%
5 years
-20.59%
 

About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Employees: 2,175

0
Funds holding %
of 6,740 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

6% more capital invested

Capital invested by funds: $665M [Q1] → $702M (+$36.8M) [Q2]

0.12% less ownership

Funds ownership: 4.19% [Q1] → 4.07% (-0.12%) [Q2]

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

10% less funds holding

Funds holding: 112 [Q1] → 101 (-11) [Q2]

46% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 24

91% less call options, than puts

Call options by funds: $1.6M | Put options by funds: $18.5M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$38
54%
upside
Avg. target
$38
54%
upside
High target
$38
54%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
JP Morgan
Anupam Rama
38% 1-year accuracy
20 / 52 met price target
54%upside
$38
Overweight
Maintained
12 Jul 2024

Financial journalist opinion

Based on 4 articles about ZLAB published over the past 30 days

Charts implemented using Lightweight Charts™